Mass Spec Enables Researchers to Identify Mutation Linked to AML; Could Lead to Dx for PGx Treatments | GenomeWeb
Researchers from five US academic labs and Cell Signaling Technology used phosphopeptide immunoprecipitation and mass spectrometry to link a new mutation in a tyrosine kinase gene to acute myeloid leukemia.
Though the results were strictly pre-clinical and were meant only to find the mutation, “the hope is that it will eventually be used for more diagnostic purposes in the clinic,” said Jeffrey Tyner, a co-author of the study and postdoc in the lab of Brian Druker at Howard Hughes Medical Institute.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.